Arca
Skip to content
Tools
Tools

Cervical cancer

Drug research and approvals for cervical cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,898 studies of cervical cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 20 drug trials for it since 2013, FDA has 0 approved and 8 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 1,898
  • Trials authorized in Canada: 20
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 1,898 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,523 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 245 whose ending is known, 36% met their primary endpoint, 7% missed it and 58% stopped early.

  • Completed, result not reported52735%
  • Ongoing46931%
  • Status unknown28219%
  • Met its primary endpoint876%
  • Stopped: other or unclear765%
  • Stopped: enrollment or feasibility382%
  • Missed its primary endpoint171%
  • Stopped: sponsor or business decision141%
  • Stopped: funding7<1%
  • Stopped: lack of efficacy3<1%
  • Stopped: safety3<1%

Trials authorized in Canada

The 10 newest of 20; search them all in Canada trials
Oct 17, 2025A phase 3, randomized, open-label, multicenter study to evaluate the efficacy and safety of sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab…MK-2870 [sacituzumab tirumotecan (SKB264)] / Keytruda [MK-3475 (pembrolizumab)]…Merck & Co. (MSD)Ongoing
Jun 13, 2024A phase 3 randomized, active-controlled, open-label, multicenter study to compare the efficacy and safety of MK-2870 monotherapy versus treatment of…MK-2870 (SKB264)Merck & Co. (MSD)Ongoing
May 30, 2024Beamion pantumor-1: a phase II, multicentre, multicohort, open label trial to evaluate the efficacy and safety of oral zongertinib (bi 1810631) for the…Zongertinib (bi 1810631)Boehringer Ingelheim (Canada) Ltd LteeOngoing
Jul 12, 2023A phase III, randomized, double blind, placebo controlled, multi centre, global study of volrustomig in women with high risk locally advanced cervical cancer…Volrustomig (MEDI5752)AstraZeneca PharmaceuticalsOngoing
Apr 28, 2021A randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage…TriapineCanadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityClosed
Feb 3, 2021A randomized, open-label, phase 3 trial of tisotumab vedotin vs investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical…Tisotumab vedotinPfizerOngoing
Apr 23, 2020A phase II, safety, and efficacy study of tiragolumab plus atezolizumab and atezolizumab monotherapy in patients with metastatic and/or recurrent…Tiragolumab (RO7092284) / Tecentriq (atezolizumab)RocheOngoing
Feb 17, 2020A randomized, phase 3, double-blind study of chemoradiotherapy with or without pembrolizumab for the treatment of high-risk, locally advanced cervical cancer…Keytruda (pembrolizumab)Merck & Co. (MSD)Ongoing
Jul 15, 2019Figo 2018 stage IB2 (>2cm - <4 cm) cervical cancer treated with neoadjuvant chemotherapyCisplatin/ Carboplatin/ PaclitaxelPrincess Margaret Cancer CentreOngoing
Apr 29, 2019Image guided intensity modulated external beam radiochemotherapy and MRI based adaptive brachytherapy in locally advanced cervical cancerGlucovisionPrincess Margaret Cancer CentrePending

FDA orphan designations

Approved first, then open designations, newest first
Aug 19, 2021Cemiplimab-rwlcTreatment of stage IA2 to stage IV cervical cancerRegeneron Pharmaceuticals, Inc.Designated
Feb 18, 2021Recombinant bispecific humanized anti-programmed cell death…Treatment of Stage IA2-IV cervical cancerAkeso Biopharma, Inc.Designated
Dec 1, 2020Human autologous CD4+ and CD8+ T cells engineered ex vivo…Treatment of patients with human papillomavirus (HPV)+ cervical cancer who are human leukocyte antigen (HLA)-A*02+Kite Pharma, Inc.Designated
Jun 26, 2020A therapeutic vaccine targeting the HPV16 E6/E7 proteinsTreatment of HPV16-positive cervical cancerISA Therapeutics BVDesignated
Apr 30, 2018Autologous tumor infiltrating lymphocytes (TIL)Treatment of cervical cancer with a tumor size greater than 2 cm. in diameterIovance Biotherapeutics, Inc.Designated
Nov 8, 20173-aminopyridine-2-carboxaldehyde thiosemicarbazoneTreatment of stage 1B to IV cervical cancerNational Cancer Institute, Div of Cancer Treatment & Diagnosis (DCTD)Designated
Mar 13, 1997PorfiromycinTreatment of cervical cancer.Boehringer Ingelheim Pharmaceuticals, Inc.Designated
Aug 24, 1994Recombinant vaccinia (human papillomavirus)Treatment of cervical cancer.Xenova Research LimitedDesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Mar 28, 2025TivdakTisotumab vedotinGenmab A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.